Published online Apr 28, 2021. doi: 10.35712/aig.v2.i2.56
Peer-review started: January 26, 2021
First decision: February 27, 2021
Revised: March 31, 2021
Accepted: April 20, 2021
Article in press: April 20, 2021
Published online: April 28, 2021
Processing time: 89 Days and 3.6 Hours
Artificial intelligence (AI) has been increasingly utilized in medical applications, especially in the field of gastroenterology. AI can assist gastroenterologists in imaging-based testing and prediction of clinical diagnosis, for examples, detecting polyps during colonoscopy, identifying small bowel lesions using capsule endoscopy images, and predicting liver diseases based on clinical parameters. With its high mortality rate, pancreatic cancer can highly benefit from AI since the early detection of small lesion is difficult with conventional imaging techniques and current biomarkers. Endoscopic ultrasound (EUS) is a main diagnostic tool with high sensitivity for pancreatic adenocarcinoma and pancreatic cystic lesion. The standard tumor markers have not been effective for diagnosis. There have been recent research studies in AI application in EUS and novel biomarkers to early detect and differentiate malignant pancreatic lesions. The findings are impressive compared to the available traditional methods. Herein, we aim to explore the utility of AI in EUS and novel serum and cyst fluid biomarkers for pancreatic cancer detection.
Core Tip: Artificial intelligence (AI) aided endoscopic ultrasound (EUS) and microRNA analyses are sensitive and effective for pancreatic cancer detection with sensitivity of more than 95%. The size of pancreatic lesion does not affect the diagnostic performance by artificial intelligence. This will help overcome the delayed diagnosis and high mortality of pancreatic cancer. Recent studies showed that the speed of AI system in EUS can be performed in real time fashion. This will be adjunctive to the conventional EUS examination for future utility.
